

# Smart Specialisation Platform for Industrial Modernisation

## Thematic S3 Partnership

*Medical technologies*

Start Date January 2017

### MONITORING PROGRESS REPORT

***Reporting Period: from January 2019 to June 2019***

This Report is presented to the relevant Working/Steering Committee.  
It contains two parts:

- I. Management Report prepared by the Lead Region(s)***
- II. Progress Report prepared by the Lead Region(s)***

The report is updated every six months.

Confidentiality: this document (part I) will be made available to the public via your Partnership's web page except for chapter *II.D. Self evaluation*.

Based on the monitoring results, the European Commission will decide on the following term's support.

**Executive summary (max. 250 words):**

*Reconciling better health / healthy ageing with growth opportunities for healthcare industries (and most notably SMEs) is the main objective of the previous Vanguard project and subsequent Industry Driven Initiative ESTHER (Emerging and Strategic Technologies for Healthcare).*

*The Medtech thematic group started in May 2016 gathering Regions, RTOs and clusters in the frame of the ESTHER / VANGUARD initiatives. In December 2016, a scoping note was written and ESTHER partners applied on the S3 platform. Auvergne- Rhône-Alpes Region is leading this Medtech partnership. Since September 2017, the Medtech platform is supported by ReConfirm initiative for developing innovative interregional projects, so called "investment protocols". A first mapping of competencies has been driven in 2017, completed and consolidated by Reconfirm in 2018. Reconfirm provides support to work on the animation of the partnership and help the group to define interregional innovative project / pilot definition and plan investments projects*

*MedTech partnership activities are centred on the development of the project identified along its activities, providing also the opportunity to partners to raise awareness around medical technologies assets and initiatives open for collaboration.*

*4 project ideas are currently supported within the framework of MedTech IM S3P partnership and one project "Medtech NetHub", coordinated by CEA (Auvergne-Rhône-Alpes), submitted an application to the TAF support programme for further development.*

## I. Management Report prepared by the Thematic Platform/Lead Region(s)

### I.A. Partnership Action Fact Sheet

- **Partnership:** *Medical technology*

- **Partnership's web-page:** <http://s3platform.jrc.ec.europa.eu/medical-technology>

- **S3 Thematic Platform:** *Industrial Modernisation*

- **Objectives:** *The main objective of the partnership is to boost investment and cooperation for facilitating, structuring and implementing strong European value chains in the field of Medical technologies. The aim is also to provide the best framework for designing projects and initiatives driven by industrials through collaborative interregional projects which could be supported at European, national and regional levels...*

- **Lead Region(s):** *list of regions/countries leading this partnership*

<i>Auvergne-Rhône-Alpes</i>
<i>Lombardy</i>
<i>Any other comments</i>

- **Official partner regions:** *list of regions/countries that have officially committed to follow this partnership and have been active in the last six months.*

<i>Baden-Württemberg (GER)</i>	<i>East Netherlands (NL)</i>	<i>South Netherlands (NL)</i>
<i>Wallonia (BEL)</i>	<i>Bretagne (FRA)</i>	<i>Thüringen (GER)</i>
<i>Vastra Götaland (SWE)</i>	<i>Catalonia (ESP)</i>	<i>Flanders (BEL)</i>
<i>Sud/PACA (FRA)</i>	<i>Grand Est (FRA)</i>	<i>Piedmont (ITA)</i>
<i>Copenhagen (DEN)</i>	<i>South Denmark (DEN)</i>	<i>Navarra (ESP)</i>
<i>Tuscany (ITA)</i>	<i>Helsinki (FIN)</i>	<i>Aragon (ESP)</i>
<i>Oulu Region (FIN), South Transdanubia (HUN), Upper Silesia (POL), Slovenia (SLO), Basque Country (ESP), NordRhein Westfalia (GER), Emilia-Romagna (ITA), Ireland (IRE), Occitanie (FRA)</i>		

- **Other regions:** *list of regions/countries that have expressed their interest in this partnership but have not signed a commitment letter).*

<i>Please enter here...</i>	<i>Please enter here...</i>	<i>Please enter here...</i>
<i>Please enter here...</i>	<i>Please enter here...</i>	<i>Please enter here...</i>
<i>Please enter here...</i>	<i>Please enter here...</i>	<i>Please enter here...</i>
<i>Please enter here...</i>	<i>Please enter here...</i>	<i>Please enter here...</i>
<i>Please enter here...</i>	<i>Please enter here...</i>	<i>Please enter here...</i>
<i>Please enter here...</i>	<i>Please enter here...</i>	<i>Please enter here...</i>
<i>Any other comments</i>		

- **Intentions to join:** *list any regional/national authorities*  
(Please list here all other regions that have expressed their interest to join the partnership)

- **Other participants (other than national/regional authorities):**  
(Please list here all other (non-region) participants (clusters, institutes, RTOs, etc.))

<i>Fondazione Regionale per la Ricerca Biomedica (Lombardy)</i>	<i>LyonBiopole (Auvergne-Rhône-Alpes)</i>	<i>CEA (Auvergne-Rhône-Alpes)</i>
<i>Campus Iberus (Aragon)</i>	<i>University of Navarra (Navarra)</i>	<i>IBEC (Catalonia)</i>

<i>IMEC (Flanders)</i>	<i>FlandersBio (Flanders)</i>	<i>DSP Valley (Flanders)</i>
<i>BioWin (Wallonia)</i>	<i>Pôle MecaTech (Wallonia)</i>	<i>EuroBioMed (Sud Provence-Alpes-Côte d'Azur)</i>
<i>BioIndustryPark (Piedmont)</i> <i>Steinbeis (Bade-Wurrtemberg)</i> <i>Bioregio STERN (Baden-Wuerttemberg)</i> <i>Alsace BioValley (Grand Est)</i> <i>CiMed (NordRhein Westfalia)</i> <i>Regional Agency (Eastern Netherland)</i> <i>Brainport Development (South Netherland)</i> <i>ASTER (Emilia - Romagna)</i> <i>Clust-ER Health (Emilia- Romagna)</i> <i>Agency for Entrepreneurship and development (Upper Silesia)</i> <i>ARAHEALTH (Aragon)</i> <i>id2santé (Bretagne)</i>		

<p><b>Representative of Lead Region 1:</b>  <i>(name, institution, address, phone, e-mail)</i>  <i>Laurence Minne - Auvergne-Rhône-Alpes Region - Research and Innovation Department</i>  <i>laurence.minne@auvergnerhonealpes.fr</i>  <i>+33426736595</i></p> <p><i>Julien Balsen - Auvergne-Rhône-Alpes EU Office in Brussels</i>  <i>julien.balsen@auvergnerhonealpes.fr</i>  <i>+33426735418</i></p>	<p><b>Representative of Lead Region 2</b>  <i>(if applicable): (name, institution, address, phone, e-mail)</i>  <i>Maria Vittoria Frau</i>  <i>Research &amp; Innovation</i>  <i>Brussels Delegation to the EU - Lombardy Region</i>  <i>2, Place du Champ de Mars</i>  <i>B-1050 Bruxelles</i>  <i>Tel. + 32 (0) 2 5187632</i>  <i>Email: maria_vittoria_frau@regione.lombardia.it</i></p>
<p><b>European Commission Coordinator:</b>  <i>(name, e-mail)</i>  <i>Nikos Pantalos (DG GROW)</i>  <i>Laurent De Mercey (DG REGIO)</i></p>	<p><b>Any other relevant information:</b>  <i>Please enter here...</i></p>

**I.B. Thematic Working Areas (WA)**

- **Thematic Working Areas** *(if any, please list of WAs, region(s) in charge of it, names and affiliations of involved regional/national authorities, and other actors)*

<i>Working Area</i>	<i>Region in Charge</i>	<i>Involved regions</i>	<i>Other actors</i>
<i>Connected Health</i>	<i>East Netherlands</i> <i>Tuscany</i> <i>Emilia Romagna</i>	<i>Lombardia, Navarra,</i> <i>Auvergne Rhône-Alpes,</i> <i>South Netherlands</i>	<i>Other actors</i>
<i>Biomaterials and implants</i>	<i>Upper Silesia</i> <i>SUD PACA</i>	<i>Navarra, Emilia-Romagna, Auvergne Rhône-Alpes, Catalonia</i>	<i>Other actors</i>
<i>Medical devices and</i>	<i>South Netherlands</i>	<i>East Netherlands,</i>	<i>Other actors</i>

<i>imaging</i>	<i>Piedmont Auvergne-Rhône-Alpes</i>	<i>Catalonia, Grand Est, Aragon, Emilia- Romagna, Lombardy, Sud</i>	
<i>Insert Working Area...</i>	<i>Region in Charge</i>	<i>Other involved regions</i>	<i>Other actors</i>
<i>Any other comments</i>			

### I.C. Overview of past activities (past six months, the 1<sup>st</sup> half of 2019)

#### Past Meetings

<i>Title</i>	<i>Date</i>	<i>Place</i>
<i>bilateral meeting between project leaders</i>	<i>12/02/2019</i>	<i>Turin</i>
<i>Medtech webinar</i>	<i>27/02/2019</i>	<i>Telco</i>
<i>MedTech Plenary &amp; S3martMed Meetings</i>	<i>02/04/2019</i>	<i>Lyon</i>
<i>Any other comments</i>		

#### Past Workshops

<i>Title</i>	<i>Date</i>	<i>Place</i>
<i>Smart Manufacturing project</i>	<i>30/04/2019</i>	<i>Go to meeting</i>
<i>Medtech NETHUB project</i>	<i>7, 24, 27 and 29/05/2019.</i>	<i>Skypemeeting</i>
<i>Medtech4 Europeworkshop - 11-13 March 2019 in Maastricht</i>		

#### Past Dissemination Activities

<i>Title</i>	<i>Date</i>	<i>Place</i>
<i>Smart Health SVC meeting</i>	<i>3/04/2019 &amp; 17/05/2019</i>	<i>Brussels</i>
<i>Medi'NOV</i>	<i>3/04/2019</i>	<i>Lyon</i>
<i>Paris Healthcare week 21 - 23/05/2019</i>		

**I.C. Overview of future activities (the next 6 months – the 2<sup>nd</sup> half of 2019)****Future Meetings**

<i>Title</i>	<i>Date</i>	<i>Place</i>
<i>IM platform SC</i>	<i>13-14 June 2019</i>	<i>Warsaw</i>
<i>Medtech Partnership plenary Meeting</i>	<i>Sept. Oct 2019</i>	<i>TBD</i>
<i>Please enter title here...</i>	<i>Please enter date here...</i>	<i>Please enter place here...</i>
<i>Any other comments</i>		

**Future Workshops**

<i>Title</i>	<i>Date</i>	<i>Place</i>
<i>Medtech NetHUB workshop</i>	<i>TBD</i>	<i>Grenoble?</i>
<i>Medtech4Europe</i>	<i>25-27/06/2019</i>	<i>Glivice (Poland)</i>
<i>Any other comments</i>		

**Future Dissemination Activities**

<i>Title</i>	<i>Date</i>	<i>Place</i>
<i>Please enter title here...</i>	<i>Please enter date here...</i>	<i>Please enter place here...</i>
<i>Please enter title here...</i>	<i>Please enter date here...</i>	<i>Please enter place here...</i>
<i>Any other comments</i>		

**II. Progress Report** prepared by the Lead Region(s) of the partnership, describing **results achieved during this period**, in no more than 3 pages (the report is “cumulative”). All items listed in Sections A, B, and C, below, must be addressed.

Additional documentation such as extended technical reports and/or proceedings of workshops may be provided separately as an annex to this report (and should be referenced in the report).

### II.A. Innovative results

- Innovative results and achievements that could be attributed to the Partnership. (Specific examples of Results vs. Objectives).

4 investments protocols are developed within the partnership and some of them are on the path of signing an Memorandum of Understanding for further involving key partners in their processes:

- Smart Manufacturing / partner lead: BioPMed: will continue its definition of topics & stakeholders to be involved in the partnership – complementarities with other initiatives supported within the partnership are explored
- Healthcare 4.0 / partner lead: Tuscany LifeScience: discussions within the potential project partnership on how to refine the scope and developments were launched by the leader, as well as 'pitch' request for next events, for disseminating upon the opportunity conferred.
- Medtech NETHUB / CEA: Bilateral / Skype exchanges to take place with existing and new participants; Kick off meeting to further agree on concepts and next steps (MoU to be discussed in line with KOM outcomes)
- Centre for Biocompatibility/GAPR: recap' of the project objectives and format

As the partnership also facilitates interactions between regional stakeholders, collaborative initiatives gathering MedTech partners are being developed/ implemented aside 'investment protocol related activities'

2 COSME projects (ESCP):

- S3SMARTMED (leader Lyonbiopole, Auvergne-Rhône-Alpes)

- AI4Diag (leader EuroBiomed, Sud PACA)

Several MedTech-related European initiatives, among which:

- MedTech4Europe - INTERREG EUROPE Call 3 (AURA)

- SAPHIRE - CSA (Flanders)

- Magia (Piedmont)

- KETGATE - INTERREG Central (Upper Silesia)

- Smart\_watch - INTERREG Central (Upper Silesia)

- ELISE - INTERREG Europe (Emilia-Romagna)

- Technological centres for industries - INTERREG P

- OCTEFA (Navarra)

- Tangible short- and medium-term socio-economic impacts achieved or expected. (Specific examples).

Structure regional innovation ecosystems in the medical technologies domain to develop interregional investments and reinforce the domain throughout Europe

Tangible S/MT impacts are complex to assess so far: while investment protocol definitions are underway, thus not yet having results to build upon, there are impacts of side projects are being developed/ implemented by partnership stakeholders, facilitated by interactions within the partnership.

### II.B. Inter-regional and inter-partnership collaborative results

- Additional results obtained from working with other partnerships under the thematic S3 Platforms. (Specific examples).

Complementarities of focus, stakeholders, etc. with the Personalised Medicine partnership were monitored, ensuring the complementarities of approaches between both partnerships.